Keraflex Keratoconus Treatment Study Begins in US

Hersh Vision Group is the First to Offer this Novel Keratoconus Treatment

Avedro, Inc. and Hersh Vision Group announced today that Dr. Peter Hersh has treated the first patient in a physician sponsored Investigational New Drug (IND) study for the Safety and Efficacy of the Keraflex Microwave System. Recruiting for additional eligible patients with keratoconus has now begun.

Dr. Hersh remarked, “Keraflex, combined with corneal collagen cross-linking, is a promising new technology to flatten the protruding cone of keratoconus and make the irregular cornea smoother. Early experience internationally has shown improvements in the keratoconic cornea that we have not seen with past technologies. This should help improve contact lens wear and vision with glasses in patients with keratoconus, a cornea problem that is difficult to correct. We hope that Keraflex can help avoid cornea transplants in many patients who otherwise might have no other alternative.”

The Keraflex refractive correction procedure is a microwave-based, non-incision ophthalmic procedure for flattening the cornea without the removal of tissue. The treatment takes less than a second, and is enhanced through a subsequent treatment of corneal collagen cross-linking using Avedro’s KXL™ accelerated cross-linking system.

“We are pleased that Dr. Hersh is able to offer Keraflex combined with KXL cross-linking as a potential treatment for his keratoconic patients,” said David Muller, PhD, CEO of Avedro. “This system has been in use outside the United States for several years and the initial studies have been very promising.” Peter S. Hersh, M.D. can be reached at the Hersh Vision Group in Teaneck, New Jersey; 201-883-0505; Keraflex has received CE Mark and is commercially available in over 30 countries. Keraflex is not approved for use in the United States.

About Avedro, Inc.

Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal cross‐linking and refractive correction. Avedro's products include capital equipment and related single dose pharmaceuticals. The KXL® System's cross‐linking, in combination with its pharmaceuticals, is used to treat keratoconus and corneal ectasia outside the United States. Those products are also used in a procedure known as Lasik Xtra®. Over 75,000 surgeries have been successfully performed outside the US using Avedro's KXL System.

Avedro distributes its products in 62 countries through 33 ophthalmic distributors with 115 sales and service representatives. Avedro products that have received CE Mark include: the KXL System for performing Lasik Xtra and Accelerated Cross‐Linking, the KXL II™ System for performing PiXL™, and the Avedro family of proprietary single dose pharmaceutical formulations.

Avedro's KXL System and single dose pharmaceutical products are currently being used in three Phase III US clinical trials involving over 100 US clinical sites. Avedro products are not for sale in the US.

Contact: David Iannetta; Avedro, Inc.;; 781‐768‐3400